Freiburg, Germany, April 23, 2026: CorTec GmbH today announced that the U.S. Food and Drug Administration (FDA) has accepted the company into its Total Product Life Cycle Advisory Program (TAP), recognizing the Brain Interchange™ BCI system as a priority innovation in stroke motor rehabilitation. The TAP enrollment follows the recently granted FDA Breakthrough Device Designation, putting CorTec among a limited number of neurotech companies to receive both recognitions. Additionally, a third patient has been successfully implanted at Harborview Medical Center in Seattle as part of the ongoing NIH-funded, FDA-approved clinical trial conducted by researchers from the University of Washington and UCLA.
Mehr erfahren Sie in der Presseinformation:
Pressemitteilung CorTec
